ReviewRSC medicinal chemistry2026
Ruthenium(ii) polypyridyl complexes and the DNA damage response: mechanisms and therapeutic implications.
Review in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ruthenium(ii) polypyridyl complexes (RPCs) have generated substantial interest due to their biomolecular binding capabilities, favourable photophysical properties, and anticancer activity. DNA is widely reported as a target for RPCs, and their recent development as photosensitisers for photodynamic therapy further emphasises DNA damage as a key biological outcome. The aim of this review is to highlight recent studies in the design of RPCs as pharmacological DNA-targeting agents and describe what is known about their impact on the DNA damage response (DDR). This, in turn, provides insight into the nature of the DNA lesions induced by these complexes. The relationship between binding mode, activation of specific DDR pathways, and resultant cell fate in human cancer cell lines is examined and, where appropriate, placed in a therapeutic context. Implications for enhancing cancer selectivity, including the use of RPCs alongside DDR inhibitors in combination strategies, as well as associated safety considerations, are discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.